(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number
WO 2005/030185 A3

(51) International Patent Classification[7]: A61K 31/137, 31/167, 31/27, 31/41, 31/4196, 31/47, 31/16, 31/165, A61P 3/06, 9/10

(21) International Application Number:
PCT/JP2004/014428

(22) International Filing Date:
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003-373453 26 September 2003 (26.09.2003) JP
60/590,811 23 July 2004 (23.07.2004) US

(71) Applicant *(for all designated States except US)*: **JAPAN TOBACCO INC.** [JP/JP]; 2-1, Toranomon 2-chome, Minato-ku, Tokyo 105-8422 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OKAMOTO, Hiroshi** [JP/JP]; c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takasuki-shi, Osaka 569-1125 (JP). **FURUKAWA, Noboru** [JP/JP]; c/o Central Pharmaceutical Research Institute of apan Tobacco Inc., 1-1, Murasaki-cho, Takasuki-shi, Osaka 569-1125 (JP). **SASASE, Tomohiko** [JP/JP]; c/o Central Pharmaceutical Research Institute of, apan Tobacco Inc., 1-1, Murasaki-cho, Takasuki-shi, Osaka 569-1125 (JP).

(74) Agent: **DAITO, Teruo**; 2nd FI, Kyowa Kogyo Bldg., 21-40 Takanawa 2-chome, Minato-ku, Tokyo 108-0074 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
11 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION

(57) Abstract: The present invention aims to provide for the treatment of hyperlipidemia, arteriosclerosis and hyper-remnant-emia, and to inhibit remnant lipoportein production by adminsetering an inhibitor of CEPT (cholesteryl ester transfer protein). Said inhibitor is a compound selected from the group cosisting of compounds of formula I to fomula XXIII, and compounds selected from the group consisting of JTT-705, CP-529414, SC-795, SC-744, SC-554, SC-71952, SC-56960, SC-57201, PD-140195, WK-5341A, WK-5344B, CETI-1 (CETP Vaccine), BM99-1 and BM99-2.

WO 2005/030185 A3